SAB Biotherapeutics CSO Charles H. Randall resigns effective Dec 31, 2021

SAB Biotherapeutics, Inc.

Charles H. Randall resigned as Chief Strategy Officer on December 31, 2021.
Company and Mr. Randall are finalizing terms of release and severance under his employment agreement.
No replacement or interim appointment has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charles H. Randall

Chief Strategy Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-12-31
Filed: January 6, 2022, 6:59 PM ET

On December 31, 2021, Charles H. Randall, Chief Strategy Officer of SAB Biotherapeutics, Inc. (the “Company”), resigned.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles H. Randall resigned as Chief Strategy Officer at SAB Biotherapeutics, Inc..

Action: resigned
Role: Chief Strategy Officer

Exact text from the filing

On December 31, 2021, Charles H. Randall, Chief Strategy Officer of SAB Biotherapeutics, Inc. (the “Company”), resigned.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-000588

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.